Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterised by unpredictable flares. Many patients with SLE are unable to achieve the recommended treatment goal of remission or the intermediate, yet still clinically beneficial, goal of Lupus Low Disease Activity State (LLD...

Descripción completa

Detalles Bibliográficos
Autor principal: Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441065/
https://www.ncbi.nlm.nih.gov/pubmed/37597847
http://dx.doi.org/10.1136/rmdopen-2023-003270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441065/
https://www.ncbi.nlm.nih.gov/pubmed/37597847
http://dx.doi.org/10.1136/rmdopen-2023-003270

Ejemplares similares